We provide our own drug-delivery platforms to improve the drug’s efficacy, direct it and reduce its side effects.
CIDETEC Nanomedicine has extensive experience in the encapsulation of antibiotics, and has solutions for both hydrophilic and hydrophobic compounds.
Projects under development include inhalation delivery.
Nanogels less than 30 nm in size obtained from a single polymer chain. They are stable systems with a controlled and precise structure that are easily functionalised. The manufacturing process is scalable and transferable to a GMP environment.
These systems allow drug encapsulation using both non-covalent interactions and bioconjugation.
Nanoformulated antibiotics with particle sizes of less than 30 nm, with antibiotic loading of up to 40% by weight. The product can be freeze-dried and is easily redispersible in water.
Antibiotics are anchored both covalently for a more sustained release, and non-covalently for a faster release, while maintaining the activity of the active ingredient.
Polysaccharide-based emulsifiers capable of generating stable oil-in-water emulsions.
Versatile technology allowing the use of different starting polysaccharides, specially dextran, hyaluronic acid and chitosan, with various oils, including active oils such as omega-3. The size of the nanoemulsions varies between 200 and 500 nm depending on the polysaccharide and the oil used.
Due to the chemistry used, the nanoemulsions degrade in the presence of lipases.
The technology uses polypeptides to generate both water-in-oil and oil-in-water nanoemulsions to encapsulate both hydrophilic and hydrophobic drugs.
The resulting nanoemulsions respond to external stimuli such as pH or the presence of certain enzymes, favouring the release of the ingredients at the action site.
Through co-developments with companies and collaborations with strategic partners, CIDETEC is developing high added value products for the pharmaceutical market.
The drug delivery systems developed are demonstrating competitive advantages in inhaled and topical delivery and regenerative medicine.
After demonstrating preclinical proof of concept, they are available for licensing.
In collaboration with Kusudama Therapeutics, CIDETEC is developing new formulations for inhaled delivery of antibiotics.
The company seeks to improve patient quality of life with formulations that allow drug dosing times to be spaced out, improving the diffusion of the antibiotics in the lung.
The technology has been designed to encapsulate hydrophobic drugs that are difficult to dissolve in water, but has demonstrated further benefits, allowing encapsulation of hydrophobic actives in the core of the nanoemulsion and hydrophilic drugs between the emulsifier.
CIDETEC has several projects underway using this technology for drug delivery. The technology has demonstrated to increase the half-life of hydrophobic active ingredients in the lungs. Other applications include the functionalisation of polymeric substrates for regenerative medicine with positive in-vivo results.
Hyaluronic acid is chemically modified for use as an emulsifier.
The nanoemulsions allow hydrophobic active ingredients to be encapsulated, seeking synergistic effects for topical skin treatments and sustained release of the active ingredients.
Patents
Applications
Single-chain nanoparticles